Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: J.F. who wrote (19345)	9/27/2006 9:53:56 AM
From: Galirayo	Respond to of 23958

Don't Harvest till it's Ripe. Torc Investments and Research Initiates Coverage of Generex Biotechnology With a Buy Rating and 12-Month Price Target of $3.00-$3.50 Wednesday September 27, 9:35 am ET TORONTO--(MARKET WIRE)--Sep 27, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News) announced today that Torc Investments and Research LLC, a NASD registered broker-dealer, initiated research coverage of the Company today with a Buy rating and a 12-month price target of $3-$3.50. biz.yahoo.com

To: J.F. who wrote (19345)	9/27/2006 10:39:05 PM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[GNBT] Another little Blurb ... Generex Biotech Rises on New Coverage By TSC Staff 9/27/2006 4:09 PM EDT Generex Biotechnology's (GNBT - commentary - Cramer's Take) stock got a lift Wednesday on new analyst coverage. Torc Investments and Research initiated coverage of the Florida-based company with a buy rating and a 12-month price target of $3-$3.50. Shares moved higher, closing Wednesday up 16 cents, or roughly 10%, at $1.76. thestreet.com